Beyond AML, PLK1 inhibition might have a role in chronic myelomonocytic leukemia (CMML) with higher expression of PLK1 in patients with RAS-pathway mutations [30]. This evidence concerns the gene PLK1 and chronic myelomonocytic leukemia.